Selected research
Industry Research
Nut Allergy Therapeutics Industry Research Report 2026
Market perspective
The global Nut Allergy Therapeutics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Nut Allergy Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Nut Allergy Therapeutics market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Nut Allergy Therapeutics market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Nut Allergy Therapeutics include J & J, HUAPONT Pharm, GSK, Bayer, Viatris, UCB Pharma, Perrigo, Kaleo and Amneal Pharma, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Nut Allergy Therapeutics market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Nut Allergy Therapeutics.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Nut Allergy Therapeutics Market by Company
J & J
HUAPONT Pharm
GSK
Bayer
Viatris
UCB Pharma
Perrigo
Kaleo
Amneal Pharma
ALK Abello
Aimmune Therapeutics
Nut Allergy Therapeutics Segment by Type
Epinephrine Injection
Antihistamines
Other
Nut Allergy Therapeutics Segment by Application
Hospital Pharmacy
Retail Pharmacy
Other
Nut Allergy Therapeutics Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nut Allergy Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nut Allergy Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nut Allergy Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Nut Allergy Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Epinephrine Injection
- Antihistamines
- Other
Applications
- Hospital Pharmacy
- Retail Pharmacy
- Other
Companies covered
- J & J
- HUAPONT Pharm
- GSK
- Bayer
- Viatris
- UCB Pharma
- Perrigo
- Kaleo
- Amneal Pharma
- ALK Abello
- Aimmune Therapeutics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Nut Allergy Therapeutics by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Epinephrine Injection
- 2.2.3 Antihistamines
- 2.2.4 Other
- 2.3 Nut Allergy Therapeutics by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital Pharmacy
- 2.3.3 Retail Pharmacy
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Nut Allergy Therapeutics Breakdown Data by Type
- 3.1 Global Nut Allergy Therapeutics Historic Market Size by Type (2021-2026)
- 3.2 Global Nut Allergy Therapeutics Forecasted Market Size by Type (2027-2032)
4 Nut Allergy Therapeutics Breakdown Data by Application
- 4.1 Global Nut Allergy Therapeutics Historic Market Size by Application (2021-2026)
- 4.2 Global Nut Allergy Therapeutics Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Nut Allergy Therapeutics Market Perspective (2021-2032)
- 5.2 Global Nut Allergy Therapeutics Growth Trends by Region
- 5.2.1 Global Nut Allergy Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Nut Allergy Therapeutics Historic Market Size by Region (2021-2026)
- 5.2.3 Nut Allergy Therapeutics Forecasted Market Size by Region (2027-2032)
- 5.3 Nut Allergy Therapeutics Market Dynamics
- 5.3.1 Nut Allergy Therapeutics Industry Trends
- 5.3.2 Nut Allergy Therapeutics Market Drivers
- 5.3.3 Nut Allergy Therapeutics Market Challenges
- 5.3.4 Nut Allergy Therapeutics Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Nut Allergy Therapeutics Players by Revenue
- 6.1.1 Global Top Nut Allergy Therapeutics Players by Revenue (2021-2026)
- 6.1.2 Global Nut Allergy Therapeutics Revenue Market Share by Players (2021-2026)
- 6.2 Global Nut Allergy Therapeutics Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Nut Allergy Therapeutics Head Office and Area Served
- 6.4 Global Nut Allergy Therapeutics Players, Product Type & Application
- 6.5 Global Nut Allergy Therapeutics Manufacturers Established Date
- 6.6 Global Nut Allergy Therapeutics Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Nut Allergy Therapeutics Market Size (2021-2032)
- 7.2 North America Nut Allergy Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Nut Allergy Therapeutics Market Size by Country (2021-2026)
- 7.4 North America Nut Allergy Therapeutics Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Nut Allergy Therapeutics Market Size (2021-2032)
- 8.2 Europe Nut Allergy Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Nut Allergy Therapeutics Market Size by Country (2021-2026)
- 8.4 Europe Nut Allergy Therapeutics Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Nut Allergy Therapeutics Market Size (2021-2032)
- 9.2 Asia-Pacific Nut Allergy Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Nut Allergy Therapeutics Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Nut Allergy Therapeutics Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Nut Allergy Therapeutics Market Size (2021-2032)
- 10.2 South America Nut Allergy Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Nut Allergy Therapeutics Market Size by Country (2021-2026)
- 10.4 South America Nut Allergy Therapeutics Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Nut Allergy Therapeutics Market Size (2021-2032)
- 11.2 Middle East & Africa Nut Allergy Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Nut Allergy Therapeutics Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Nut Allergy Therapeutics Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 J & J
- 12.1.1 J & J Company Information
- 12.1.2 J & J Business Overview
- 12.1.3 J & J Revenue in Nut Allergy Therapeutics Business (2021-2026)
- 12.1.4 J & J Nut Allergy Therapeutics Product Portfolio
- 12.1.5 J & J Recent Developments
- 12.2 HUAPONT Pharm
- 12.2.1 HUAPONT Pharm Company Information
- 12.2.2 HUAPONT Pharm Business Overview
- 12.2.3 HUAPONT Pharm Revenue in Nut Allergy Therapeutics Business (2021-2026)
- 12.2.4 HUAPONT Pharm Nut Allergy Therapeutics Product Portfolio
- 12.2.5 HUAPONT Pharm Recent Developments
- 12.3 GSK
- 12.3.1 GSK Company Information
- 12.3.2 GSK Business Overview
- 12.3.3 GSK Revenue in Nut Allergy Therapeutics Business (2021-2026)
- 12.3.4 GSK Nut Allergy Therapeutics Product Portfolio
- 12.3.5 GSK Recent Developments
- 12.4 Bayer
- 12.4.1 Bayer Company Information
- 12.4.2 Bayer Business Overview
- 12.4.3 Bayer Revenue in Nut Allergy Therapeutics Business (2021-2026)
- 12.4.4 Bayer Nut Allergy Therapeutics Product Portfolio
- 12.4.5 Bayer Recent Developments
- 12.5 Viatris
- 12.5.1 Viatris Company Information
- 12.5.2 Viatris Business Overview
- 12.5.3 Viatris Revenue in Nut Allergy Therapeutics Business (2021-2026)
- 12.5.4 Viatris Nut Allergy Therapeutics Product Portfolio
- 12.5.5 Viatris Recent Developments
- 12.6 UCB Pharma
- 12.6.1 UCB Pharma Company Information
- 12.6.2 UCB Pharma Business Overview
- 12.6.3 UCB Pharma Revenue in Nut Allergy Therapeutics Business (2021-2026)
- 12.6.4 UCB Pharma Nut Allergy Therapeutics Product Portfolio
- 12.6.5 UCB Pharma Recent Developments
- 12.7 Perrigo
- 12.7.1 Perrigo Company Information
- 12.7.2 Perrigo Business Overview
- 12.7.3 Perrigo Revenue in Nut Allergy Therapeutics Business (2021-2026)
- 12.7.4 Perrigo Nut Allergy Therapeutics Product Portfolio
- 12.7.5 Perrigo Recent Developments
- 12.8 Kaleo
- 12.8.1 Kaleo Company Information
- 12.8.2 Kaleo Business Overview
- 12.8.3 Kaleo Revenue in Nut Allergy Therapeutics Business (2021-2026)
- 12.8.4 Kaleo Nut Allergy Therapeutics Product Portfolio
- 12.8.5 Kaleo Recent Developments
- 12.9 Amneal Pharma
- 12.9.1 Amneal Pharma Company Information
- 12.9.2 Amneal Pharma Business Overview
- 12.9.3 Amneal Pharma Revenue in Nut Allergy Therapeutics Business (2021-2026)
- 12.9.4 Amneal Pharma Nut Allergy Therapeutics Product Portfolio
- 12.9.5 Amneal Pharma Recent Developments
- 12.10 ALK Abello
- 12.10.1 ALK Abello Company Information
- 12.10.2 ALK Abello Business Overview
- 12.10.3 ALK Abello Revenue in Nut Allergy Therapeutics Business (2021-2026)
- 12.10.4 ALK Abello Nut Allergy Therapeutics Product Portfolio
- 12.10.5 ALK Abello Recent Developments
- 12.11 Aimmune Therapeutics
- 12.11.1 Aimmune Therapeutics Company Information
- 12.11.2 Aimmune Therapeutics Business Overview
- 12.11.3 Aimmune Therapeutics Revenue in Nut Allergy Therapeutics Business (2021-2026)
- 12.11.4 Aimmune Therapeutics Nut Allergy Therapeutics Product Portfolio
- 12.11.5 Aimmune Therapeutics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst